Wang Guoliang, Bi Hai, Ye Jianfei, Zhang Hongxian, Hou Xiaofei, Liu Cheng, Qiu Min, Tian Yu, Kaushik Dharam, Ma Lulin
Department of Urology, Peking University Third Hospital, Beijing, China.
Division of Urologic Oncology, Department of Urology, University Texas Health Science Center, San Antonio, TX, USA.
J Int Med Res. 2020 Nov;48(11):300060520962288. doi: 10.1177/0300060520962288.
We investigated the safety and effectiveness of a modified transabdominal approach for renal cell carcinoma (RCC) with a supradiaphragmatic inferior vena cava (IVC) tumor thrombus (TT).
Eight patients underwent radical nephrectomy with removal of a supradiaphragmatic IVC-TT through an abdominal incision using a transdiaphragmatic approach in Peking University Third Hospital from April 2015 to January 2018. We modified this technique using a Foley catheter balloon to avoid piggyback liver mobilization.
All patients underwent successful operations. The median operative time was 7 hours 23 minutes. The median estimated blood loss was 2963 mL. All patients received a blood transfusion with a median blood infusion volume of 2162 mL. Two patients with Budd-Chiari syndrome developed postoperative ascites and hydrothorax due to non-watertight repair of the diaphragm. During a follow-up of 11 to 44 months, only one patient died of liver metastasis and four patients developed distant metastasis without recurrence in the IVC.
The modified transabdominal approach described herein has an encouraging safety profile and provides a surgical option for treatment of RCC with a supradiaphragmatic IVC-TT. More evidence concerning the beneficial role of this procedure will be elucidated in further studies.
我们研究了一种改良经腹入路治疗伴有膈上腔静脉(IVC)肿瘤血栓(TT)的肾细胞癌(RCC)的安全性和有效性。
2015年4月至2018年1月,8例患者在北京大学第三医院接受了根治性肾切除术,采用经膈入路通过腹部切口切除膈上IVC-TT。我们改良了该技术,使用Foley导尿管球囊以避免附加肝游离。
所有患者手术均成功。中位手术时间为7小时23分钟。中位估计失血量为2963 mL。所有患者均接受输血,中位输血量为2162 mL。2例布加综合征患者因膈肌修复不严密出现术后腹水和胸腔积液。在11至44个月的随访中,仅1例患者死于肝转移,4例患者出现远处转移,IVC无复发。
本文所述的改良经腹入路具有令人鼓舞的安全性,为治疗伴有膈上IVC-TT的RCC提供了一种手术选择。该手术有益作用的更多证据将在进一步研究中阐明。